timothy sykes logo
Cidara Therapeutics’ Big Move: What’s Next? Thumbnail
ADD US ONG Google News

Cidara Therapeutics’ Big Move: What’s Next?

BRYCE TUOHEY•UPDATED NOV. 14, 2025, 2:33 PM ET
Reviewed by Matt Monaco Fact-checked by Bryce Tuohey

Cidara Therapeutics Inc.’s stocks have been trading up by 105.49 percent amid FDA designations and promising results boosting investor confidence.

  • Conversations are buzzing in corporate boardrooms, as Cidara nears a potential acquisition deal with Merck. This merger illustrates significant buyout interest from the major player in the pharmaceutical industry, following a competitive bidding process.

  • Stock analysts have their eyes locked on Cidara, with H.C. Wainwright reiterating it as a top pick. After showcasing promising data on CD388, they’ve bolstered confidence in Cidara’s ability to handle diverse types of influenza.

  • A nod from Morgan Stanley speaks volumes. They’ve kicked off coverage of Cidara Therapeutics with an “Overweight” rating accompanied by a $190 price target, spotlighting the company’s potential in flu prevention.

  • Impressive advancements in CD388’s Phase 3 enrollment have sparked RBC Capital to raise Cidara’s price target to $145, maintaining their “Outperform” rating. The current share price hints at a promising rise aligned with these assessments.

Candlestick Chart

Live Update At 14:32:49 EST: On Friday, November 14, 2025 Cidara Therapeutics Inc. stock [NASDAQ: CDTX] is trending up by 105.49%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Financial Health Overview: Earnings and Figures

As millionaire penny stock trader and teacher Tim Sykes, says, “It’s not about how much money you make; it’s about how much money you keep.” Successful trading requires a mindset focused on not just generating profits but also preserving them. Many novice traders focus on the allure of large profits, but seasoned traders understand that effectively managing risk and capital is crucial. By controlling expenses and avoiding unnecessary losses, traders can ensure they retain more of their hard-earned money, ultimately leading to sustainable trading success.

The financial backdrop of Cidara Therapeutics reveals a complex yet intriguing story. For the period ending Sep 30, 2025, the company recorded a challenging quarter as reflected by the dropping EPS. With significant losses against quarterly norms, the Q3 earnings showed an EPS of ($3.10) compared to a consensus of ($1.33). Despite the EPS tumble, the company’s stable cash flow and strength in ongoing Phase 3 efforts illuminate a silver lining of prospect.

A sharp dive into the numbers shows a total revenue of $1.275M with alarming financial ratios, indicative of a young and growing company raised on innovation rather than immediate profit. A high price to sales ratio at 2,641 underscores the pivotal anticipation of future earnings rather than present profitability.

Economic Dynamics: Stock Performance Insights

In recent weeks, Cidara’s stock journey has unfolded a narrative filled with crests and troughs. A noticeable spike emerged during November, where prices steadily climbed from $96.70 to a closing of $217.85 on Nov 14, 2025. Analysts speculate this upward trend is fueled by positive momentum from CD388’s development, investor confidence buoyed by acquisition talks, and strategic financial ratings.

Still, its potential remains double-edged. Rapid gains, characteristic of biotech ventures, are infused with speculation and anticipation. Will Cidara sustain or falter amidst pharmaceutical market fluctuations? Only time will reveal.

More Breaking News

News and Market Implications: Interpretation and Analysis

Give Cidara’s latest developments a glance, and it’s clear the company is forging ahead. Its continued success with CD388 stands as a key pillar of corporate strategy. The innovation strength of flu-preventative efforts caught Merck’s eye, leading to discussions for acquisition—a move brimming with influence over market dynamics.

Underpinning this momentum is the firm faith of financial institutions, like Morgan Stanley and RBC Capital, assigning weight to Cidara’s future potential. As the flu season peaks, anticipation of CD388’s role in providing a solution becomes a critical factor for those weighing in.

In conclusion, Cidara Therapeutics showcases a fascinating juncture of high stakes, both in groundbreaking medicinal advancement and market potential. Whether standing tall on its scientific breakthroughs or merging into a larger entity, its path is laden with opportunity and challenges. Traders and onlookers alike should brace for a rollercoaster of strategic swings. As millionaire penny stock trader and teacher Tim Sykes says, “Be patient, don’t force trades, and let the perfect setups come to you.” This wisdom is particularly relevant in the context of such dynamic market conditions.

The unrelenting buzz around Cidara reflects a vibrant ecosystem where science, commerce, and speculation coexist. Adapting to these movements requires nimble decisions, grounded in both current achievements and speculative visions of what lies ahead.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading CDTX

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”